Latanoprost Stallpharma

Latanoprost, the active ingredient in Latanoprost Stallpharma, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It lowers intra‑ocular pressure and is indicated for the management of open‑angle glaucoma and ocular hypertension in adult patients.\n\nGNH India supplies Latanoprost Stallpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost Stallpharma is a prostaglandin analog used to manage conditions that involve elevated intra‑ocular pressure.\n\n- Open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression.\n- Ocular hypertension: lowers pressure to prevent conversion to glaucoma.

Latanoprost may cause ocular and systemic reactions.\n\nCommon Side Effects:\n- Eye redness: mild conjunctival hyperemia.\n- Increased eyelash growth: longer, thicker lashes.\n- Iris darkening: gradual pigmentation change.\n- Eye irritation: burning or stinging sensation.\n- Blurred vision: transient visual disturbance.\n\nSerious or Rare Side Effects:\n- Severe eye inflammation: uveitis or iritis requiring medical attention.\n- Allergic reaction: swelling, rash, or difficulty breathing.\n- Vision loss: sudden decrease in visual acuity.\n- Ocular infection: signs of bacterial or fungal infection.

Before using Latanoprost Stallpharma, consider the following precautions.\n\n- Monitor intra‑ocular pressure: ensure therapeutic response and adjust therapy if needed.\n- Assess for ocular infections: avoid use if active infection is present.\n- Avoid contact lens wear initially: discontinue lenses for at least 24 hours after instillation.\n- Inform ophthalmologist of systemic diseases: especially asthma or cardiovascular conditions.\n- Store at room temperature: keep bottle tightly closed, protect from light and moisture.

Latanoprost may interact with other ophthalmic or systemic agents.\n\nMajor Interactions (Avoid):\n- Non‑steroidal anti‑inflammatory eye drops: may diminish latanoprost efficacy.\n- Systemic prostaglandin analogs: additive effect on intra‑ocular pressure reduction.\n\nModerate Interactions (Monitor Closely):\n- Beta‑blocker eye drops: combined IOP‑lowering effect may be excessive.\n- Carbonic anhydrase inhibitor eye drops: enhanced pressure‑lowering response.\n- Anticholinergic agents: possible alteration of pupil dynamics.